Evergreen Theragnostics, a clinical-stage radiopharmaceutical company, today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT. The financing advances Evergreen’s novel discovery pipeline into clinical trials, supports commercialization of its diagnostic agent, and further expands CDMO capabilities to
NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces a further extension of £9.6m (approx. USD $12.2m) to its Series B financing round. With participation from its existing syndicate, CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, 2investAG, and the addition of three
1000Farmacie, the leading Italian pharmacy marketplace, announced today the successful completion of its second tranche of Series A funding, raising a total of $25 million. The company secured an additional $10 million in the extension round, highlighting investor confidence and further accelerating the company's mission to revolutionize the pharmaceutical industry.
Easyrain is undergoing a capital increase and preparing for collaborations with a Tier-1 company and an automotive manufacturer. Barely we had time to tone down the enthusiasm from the successful participation in the Goodwood Festival of Speed, and it's already time to announce a new and significant milestone: Easyrain announces
Copenhagen, Denmark - Sparrow Quantum Aps., a quantum technology company based in Denmark, announced today that it had secured 31 million DKK (€4.1m) in seed funding, the largest investment to date in a Danish quantum technology company. The funding round was led by the venture capital firm 2xN and includes
LIFTTand the Venture Capital fund set up by the European Commission (EC) bet on artificial intelligence used in the professional dubbing sector, a 10-billion-dollar market. The evergreen Venture Capital Holding LIFTT—as lead Investor—and the European Innovation Council Fund (EIC Fund) are investing 1 million euros in Voiseed, the Italian
“The innovation made by Careglance allows for a much faster surface analysis speed as well as considerably reducing the size of the OCT device.” LIFTT is participating with a EUR 250,000 investment in Care Glance, a deep tech start-up operating in the field of micro-optical diagnostics, which has developed and
“BetaGlue brings together some of the world’s excellence in the field of cancer fighting, and their insight to combine existing and already active technologies in the market in an innovative way is simply formidable.”This month, we announced our investment in BetaGlue Technologies, a highly innovative life science company that we
Habacus was born in 2017 from an initiative of the current CEO Paolo Cuniberti, who has almost thirty years of experience in the financial sector in investment banks and international finance that led him to found this company to bring innovation to the model of student loans for students in
“We want to become a major player that can enable even more sustainable material design and waste management strategies for the rubber industry.” Rubber Conversion and LIFTT met in September 2020, as a Spin-off opportunity for a company already active in the world of circular economy and closed loops. The
VAT n. 12013790014
Shared Capital
€ 100.835.954,00 authorised,
€ 43.482.552,00 paid,
€ 40.000.000,00 as per last statutory financial statements.
LIFTT S.p.A. adopts an Organization, Management and Control Model in line with the provisions of Legislative Decree 231/2001, and the Code of Ethics as completing part of the Model.